The correlation of IDO activity and expression at the tumour, draining lymph nodes, and in peripheral blood can potentially lead to less invasive sentinel lymph node and liquid biopsies to inform stratified, personalised HNSCC immune‐based therapy. The gene discussed is IDO1; the disease is head and neck squamous cell carcinoma.